Rivaroxaban data abound at ESC 2018 - podcast episode cover

Rivaroxaban data abound at ESC 2018

Aug 28, 20189 minSeason 1Ep. 147
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

New results from the ASCEND trial snow that neither aspirin nor fish oil provide any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Rivaroxaban data abound at ESC 2018 | Daily Medical News podcast - Listen or read transcript on Metacast